BACKGROUND: @entity5697 ( @entity5697 ) associated with @entity1652 ( @entity1652 ) can be severe and is well known to reduce mobility early in the disease. However the burden of @entity1494 is unknown and overlooked. We studied the frequency of @entity1494 and their impact on quality of life. METHODS: A cross-sectional study of 60 @entity1 who had @entity3951 -IgG positive @entity1652 associated @entity5697 was performed using the Bladder Control Scale, Lower Urinary Tract Quality of Life, Bowel Control Scale and Neurogenic Bowel Score, Short-Form-36 Health Survey and EDSS. The relationships between the variables were analysed with multiple linear regression. RESULTS: Fifty @entity1 and 10 @entity1 participated. 78% (47/60) @entity1 reported @entity1494 and a similar number reported bowel problems. 87% (52/60) @entity1 reported either @entity1494 . 65% (39/60) developed residual symptoms after the first episode of @entity4685 and the remaining by the second episode. Both @entity1494 reduced quality of life and required modification of lifestyle in 83% (39/47) and 70% (33/47) respectively. CONCLUSION: Bladder and @entity29 is very common in @entity1652 associated @entity4685 developing early in the disease and significantly affects quality of life.

Bladder and @entity29 affect quality of life. A cross sectional study of 60 @entity1 with XXXX antibody positive @entity1652 .

@entity5697 :: ('MESH:D009188', 'Disease') :: ['TM', 'Transverse myelitis'] @entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder and bowel dysfunction', 'bladder symptoms', 'bladder or bowel dysfunction'] @entity1652 :: ('MESH:D009471', 'Disease') :: ['Neuromyelitis Optica', 'NMO'] @entity29 :: ('MESH:D015212', 'Disease') :: ['bowel dysfunction'] @entity3951 :: ('361', 'Gene') :: ['AQP4'] @entity4685 :: ('MESH:D009187', 'Disease') :: ['myelitis']
@entity3951 :: (361,Gene) :: ['aquaporin-4']
